LAUSR

Hepatocellular carcinoma (HCC) incidence in the U.S. is increasing in specific subgroups of patients such as white men with hepatitis C and Hispanics with non-alcoholic fatty liver disease.(1) HCC is the only cancer type with increased mortality over the past three decades throughout the nation, and with still dismal 5-year survival less than 18%.(2) HCC chemoprevention in individuals at high risk is likely the most impactful strategy to improve patient prognosis, although no such therapy has been established to date after a series of failed clinical trials of agents such as low-dose interferon. This article is protected by copyright. All rights reserved.